🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The study is being conducted to evaluate the efficacy, and safety of camrel...
Status
Unknown
Location
The First Affiliated Hospital of Bengbu Medical College
Start Date
2022-09-08
Trial ID
NCT05042375
Treatments Being Tested
The study is being conducted to evaluate the Famitinib with Camrelizumab pl...
Status
Recruiting
Location
Breast cancer institute of Fudan University Cancer Hospital
Start Date
2023-03-17
Trial ID
NCT05760378
Treatments Being Tested
This study is a prospective, single-center, open-label, umbrella-shaped pha...
Status
Unknown
Location
Cancer Hospital Affiliated to Fudan University
Start Date
2020-05-01
Trial ID
NCT04355858
The primary objective of the study was to assess the effect of repeated ora...
Status
Completed
Location
Affiliated Hospital of Qingdao University
Start Date
2020-07-20
Trial ID
NCT04494659
Treatments Being Tested
The purpose of this study is to establish a prospective, single-center plat...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Start Date
2022-11-01
Trial ID
NCT05582499
Treatments Being Tested
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, V...
Status
Completed
Location
Cancer center, Sun Yet-sen University
Start Date
2012-04
Trial ID
NCT01762293
This study is being conducted to explore the efficacy and safety of SHR-102...
Status
Unknown
Location
Tianjin Medical University Cancer Institute and Hospital
Start Date
2021-04-22
Trial ID
NCT04814485
Treatments Being Tested
The study is being conducted to evaluate the efficacy and safety of SHR-121...
Status
Terminated
Location
Beijing Cancer Hosipital
Start Date
2021-02-01
Trial ID
NCT04619433
This study is being conducted to explore the efficacy of SHR-6390 and SHR-1...
Status
Unknown
Location
Tianjin Medical University Cancer Institute and Hospital
Start Date
2021-04
Trial ID
NCT04866381
Treatments Being Tested
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, V...
Status
Suspended
Location
Cancer Hospital of Guangzhou Sun Yat-sen University
Start Date
2014-12
Trial ID
NCT02356991